- Home
- EXEL vs EVR Comparison
EXEL vs EVR Comparison
Compare EXEL & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | EVR |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.7B |
| IPO Year | 2000 | 2006 |
Fundamental Metrics
Financial Performance| Metric | EXEL | EVR |
|---|---|---|
| Price | $57.57 | $272.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 8 |
| Target Price | $46.50 | ★ $359.38 |
| AVG Volume (30 Days) | ★ 1.8M | 412.5K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | ★ 57.95 | 54.74 |
| EPS | 1.60 | ★ 9.56 |
| Revenue | $452,477,000.00 | ★ $3,880,084,000.00 |
| Revenue This Year | $13.61 | $22.69 |
| Revenue Next Year | $13.13 | $13.31 |
| P/E Ratio | $35.76 | ★ $28.14 |
| Revenue Growth | N/A | ★ 29.49 |
| 52 Week Low | $33.76 | $258.61 |
| 52 Week High | $59.72 | $388.71 |
Technical Indicators
Market Signals| Indicator | EXEL | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 34.37 |
| Support Level | $54.38 | $265.87 |
| Resistance Level | $59.72 | $353.60 |
| Average True Range (ATR) | 1.50 | 8.00 |
| MACD | -0.06 | -0.68 |
| Stochastic Oscillator | 55.36 | 25.76 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About EVR Evercore Inc.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.